SCI
TVTX icon

S&CO Inc’s Travere Therapeutics TVTX Stock Holding History

S&CO Inc’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.18M Hold
56,000
– – 0.18% 89
2026
Q1 		$1.66M Hold
56,000
– – 0.1% 120
2025
Q4 		$2.14M Hold
56,000
– – 0.13% 114
2025
Q3 		$1.34M Buy
56,000
+28,000
+100% +$526K 0.08% 132
2025
Q2 		$414K Buy
+28,000
New +$464K 0.03% 178

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

S&CO Inc's TVTX Position: Q2 2026 in Review

S&CO Inc held its Travere Therapeutics (TVTX) position steady in Q2 2026 at 56,000 shares worth $3.18M. The position accounts for 0.18% of the portfolio, ranked #89.

S&CO Inc first reported a position in TVTX in Q2 2025 and has held it in 5 quarters since. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • S&CO Inc held 56,000 shares of Travere Therapeutics worth $3.18M as of Q2 2026.
  • S&CO Inc left its Travere Therapeutics share count unchanged in Q2 2026.
  • Travere Therapeutics made up 0.18% of S&CO Inc's portfolio in Q2 2026, its #89 holding.
  • S&CO Inc first reported a position in Travere Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on S&CO Inc's 13F filing for Q2 2026, filed 6 Aug 2026.